Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
68.88
+3.25 (4.95%)
At close: Feb 3, 2026, 4:00 PM EST
68.89
+0.01 (0.01%)
After-hours: Feb 3, 2026, 4:10 PM EST
Apogee Therapeutics Employees
Apogee Therapeutics had 196 employees as of December 31, 2024. The number of employees increased by 105 or 115.38% compared to the previous year.
Employees
196
Change (1Y)
105
Growth (1Y)
115.38%
Revenue / Employee
n/a
Profits / Employee
-$1,294,255
Market Cap
4.65B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 196 | 105 | 115.38% |
| Dec 31, 2023 | 91 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 685 |
| ACADIA Pharmaceuticals | 654 |
| Corcept Therapeutics | 500 |
| Amicus Therapeutics | 499 |
| CRISPR Therapeutics AG | 393 |
| TG Therapeutics | 374 |
| Arcellx | 163 |
| Scholar Rock Holding | 128 |
APGE News
- 13 days ago - Apogee Therapeutics: 2026 Inflection Point In Immunology - Seeking Alpha
- 4 weeks ago - Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript - Seeking Alpha
- 4 weeks ago - Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - GlobeNewsWire
- 4 weeks ago - Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 - GlobeNewsWire
- 2 months ago - Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - GlobeNewsWire
- 3 months ago - Apogee Therapeutics to Participate in Upcoming Conferences - GlobeNewsWire